- Home
- NVT vs WAT Comparison
NVT vs WAT Comparison
Compare NVT & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVT
- WAT
- Stock Information
- Founded
- NVT 1903
- WAT 1958
- Country
- NVT United Kingdom
- WAT United States
- Employees
- NVT N/A
- WAT N/A
- Industry
- NVT Industrial Machinery/Components
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- NVT Industrials
- WAT Industrials
- Exchange
- NVT Nasdaq
- WAT Nasdaq
- Market Cap
- NVT 15.3B
- WAT 17.8B
- IPO Year
- NVT N/A
- WAT 1995
- Fundamental
- Price
- NVT $96.53
- WAT $303.66
- Analyst Decision
- NVT Strong Buy
- WAT Hold
- Analyst Count
- NVT 11
- WAT 14
- Target Price
- NVT $83.09
- WAT $374.07
- AVG Volume (30 Days)
- NVT 1.6M
- WAT 582.8K
- Earning Date
- NVT 10-31-2025
- WAT 10-31-2025
- Dividend Yield
- NVT 0.83%
- WAT N/A
- EPS Growth
- NVT 2.58
- WAT 10.77
- EPS
- NVT 3.51
- WAT 11.09
- Revenue
- NVT $3,306,600,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- NVT $26.18
- WAT $7.19
- Revenue Next Year
- NVT $10.33
- WAT $6.40
- P/E Ratio
- NVT $27.44
- WAT $27.46
- Revenue Growth
- NVT 14.92
- WAT 5.89
- 52 Week Low
- NVT $41.71
- WAT $275.05
- 52 Week High
- NVT $97.52
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- NVT 68.64
- WAT 53.25
- Support Level
- NVT $94.55
- WAT $294.96
- Resistance Level
- NVT $97.52
- WAT $303.24
- Average True Range (ATR)
- NVT 2.21
- WAT 9.27
- MACD
- NVT 0.12
- WAT 0.81
- Stochastic Oscillator
- NVT 90.40
- WAT 69.33
About NVT nVent Electric plc
NVent is a leading global provider of electrical connection and protection solutions that touch a broad range of end markets, including infrastructure, industrial, commercial, and residential. NVent designs, manufactures, markets, installs, and services a portfolio of electrical enclosures and electrical fastening solutions. North America accounts for the majority of sales.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.